HPS3/TIMI 55 REVEAL

HPS3/TIMI 55 REVEAL assessed the effect of cholesterol ester transfer protein (CETP) inhibition with anacetrapib 100 mg versus matching placebo on time to first major coronary event among 30,000 individuals with pre-existing vascular disease.

MAIN RESULTS:
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
N Engl J Med. 2017 Sep 28;377(13):1217-1227.

PRESENTATIONS

ESC 2017
Comparing Biomarker Profiles in Patients with Stable Atherosclerosis Treated with Anacetrapib versus Placebo: a Nested Proteomic Study from HPS3/TIMI 55-REVEAL (Berg, ESC 2019)
Biomarker-Based Heart Failure Risk Stratification in Patients with Atherosclerotic Cardiovascular Disease: Observations From HPS3 TIMI-55 REVEAL (Berg, AHA 2020)
Concurrent Evaluation Of HSTNI And HSTNT And Their Associations With Cardiovascular Events In 37,886 Patients With Stable Atherosclerotic Cardiovascular Disease (Bajaj, ACC 2024)

OTHER PUBLICATIONS

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J. 2017 May;187:182-190.

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA Cardiol. 2018 Sep 1;3(9):823-828. 

Impact of ADCY9 Genotype on Response to Anacetrapib. Circulation. 2019 Jul 23;140(11):891-898.